Funded Startups in Nijmegen
Seventeen funded startups in Nijmegen (rows spanning 2020-05-18 to 2026-04-17) show a clear size split: the largest disclosed round is ScreenPoint Medical’…
Seventeen funded startups in Nijmegen (rows spanning 2020-05-18 to 2026-04-17) show a clear size split: the largest disclosed round is ScreenPoint Medical’s $14M (2026-04-17), and no other disclosed amount comes close to that level—SolarDuck’s $16M (2023-12-21) is actually the only higher disclosed figure, while most others cluster between $2M and $12M (e.g., QurieGen $2M on 2025-04-08; Enzyre $12M on 2022-11-02). The list also has an “unknown/undisclosed” funding-amount pattern: 3 of 17 rows are explicitly undisclosed (Salesupply on 2025-01-01; 1-2-Taste on 2023-06-15; and one more undisclosed row is not present—so the count is two undisclosed rows, with the rest showing dollar amounts), and “Series Unknown” appears repeatedly as a classification (covering multiple post-2023 deals).
On sectors and timing, life sciences and healthcare are frequent: Biotechnology and Health/Health Care each recur across multiple companies (e.g., ATRO Medical 2026-02-24, Khondrion 2025-05-06, Alveron Pharma 2024-12-06; and CardiacBooster 2025-08-07, Enzyre 2022-11-02, Pleco Therapeutics 2022-09-06). Temporally, entries concentrate toward the right edge of the table: the most recent 6 rounds run from 2025-08-07 (CardiacBooster) through 2026-04-17 (ScreenPoint Medical), suggesting ongoing fundraising rather than a one-off wave.
Most recent rounds
17 shownRelated listings
Frequently asked
What are the biggest disclosed rounds shown, and how much larger are they versus the rest of the list?
SolarDuck’s $16M (2023-12-21) and ScreenPoint Medical’s $14M (2026-04-17) are the top disclosed amounts in these 17 rows; most other disclosed deals sit notably below that range, such as Enzyre $12M (2022-11-02) and Pleco Therapeutics $17M (2022-09-06) and others at $11M (CardiacBooster 2025-08-07) or $6M (Khondrion 2025-05-06).
Do multiple deals cluster in a narrow time window among the most recent entries?
Yes. Six of the 17 rows fall between 2025-08-07 (CardiacBooster) and 2026-04-17 (ScreenPoint Medical), including $11M on 2025-08-07, $6M on 2025-05-06 (Khondrion), and $3M on 2025-09-12 (Aiosyn).
Are any sectors over-represented compared with others in this Nijmegen slice?
Biotechnology appears in at least four distinct companies (ATRO Medical 2026-02-24, Khondrion 2025-05-06, QurieGen 2025-04-08, Alveron Pharma 2024-12-06). Health/Health Care also recurs across multiple entries such as CardiacBooster (2025-08-07, $11M), Enzyre (2022-11-02, $12M), and Pleco Therapeutics (2022-09-06, $17M).
How often are funding amounts or round types not specified, and does that affect the ability to identify outliers?
Two of 17 rows list the amount as undisclosed (Salesupply on 2025-01-01 and 1-2-Taste on 2023-06-15), and multiple rows use “Series Unknown” as the round classification (for example ScreenPoint Medical 2026-04-17 and CardiacBooster 2025-08-07). That means comparisons of “largest/smallest” rely only on the disclosed-dollar rows, where the top disclosed figures are in the mid-teens.
Which entries look like material outliers to review first for investor diligence?
SolarDuck’s $16M (2023-12-21) and Pleco Therapeutics’ $17M (2022-09-06) are the two disclosed highs in this list, materially above many other disclosed rounds like QurieGen $2M (2025-04-08) and Aiosyn $2M (2022-12-21). Together they stand out as the upper tail of disclosed amounts in Nijmegen within the displayed time range.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.